Race Oncology Limited (RAONF)
USD 1.22
(0.0%)
USD 1.22
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 20.22 Million AUD | -24.06% |
| 2023 | 17.74 Million AUD | -31.48% |
| 2022 | 25.89 Million AUD | 142.1% |
| 2021 | 10.69 Million AUD | 161.79% |
| 2020 | 4.08 Million AUD | 11.06% |
| 2019 | 3.67 Million AUD | -39.58% |
| 2018 | 6.08 Million AUD | 32.27% |
| 2017 | 4.6 Million AUD | 38.31% |
| 2016 | 3.32 Million AUD | 2573.81% |
| 2015 | 124.46 Thousand AUD | 101.4% |
| 2014 | 61.8 Thousand AUD | -41.27% |
| 2013 | 105.22 Thousand AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 21.07 Million USD | 0.0% |
| 2024 Q4 | 20.22 Million AUD | 0.0% |
| 2024 Q1 | 21.07 Million AUD | 18.77% |
| 2023 Q2 | 31.58 Million USD | 0.0% |
| 2023 Q4 | 17.74 Million AUD | -33.4% |
| 2023 Q3 | 26.63 Million AUD | -15.67% |
| 2023 Q1 | 31.58 Million AUD | 22.0% |
| 2023 FY | 17.74 Million AUD | -31.48% |
| 2022 Q1 | 42.06 Million AUD | 293.34% |
| 2022 FY | 25.89 Million AUD | 142.1% |
| 2022 Q4 | 25.89 Million AUD | -31.0% |
| 2022 Q3 | 37.52 Million AUD | -10.8% |
| 2022 Q2 | 42.06 Million USD | 0.0% |
| 2021 Q4 | 10.69 Million AUD | -24.92% |
| 2021 Q3 | 14.24 Million AUD | 49.11% |
| 2021 Q1 | 9.55 Million AUD | 133.86% |
| 2021 Q2 | 9.55 Million USD | 0.0% |
| 2021 FY | 10.69 Million AUD | 161.79% |
| 2020 Q2 | 5.68 Million USD | 0.0% |
| 2020 Q3 | 5.93 Million AUD | 4.44% |
| 2020 Q4 | 4.08 Million AUD | -31.15% |
| 2020 FY | 4.08 Million AUD | 11.06% |
| 2020 Q1 | 5.68 Million AUD | 54.45% |
| 2019 Q3 | 5.24 Million AUD | -22.05% |
| 2019 Q1 | 6.72 Million AUD | -18.39% |
| 2019 FY | 3.67 Million AUD | -39.58% |
| 2019 Q4 | 3.67 Million AUD | -29.83% |
| 2019 Q2 | 6.72 Million AUD | 0.0% |
| 2018 Q1 | 5.97 Million AUD | -0.44% |
| 2018 FY | 6.08 Million AUD | 32.27% |
| 2018 Q4 | 8.24 Million AUD | 0.0% |
| 2018 Q3 | 8.24 Million AUD | 37.93% |
| 2018 Q2 | 5.97 Million AUD | 0.0% |
| 2017 Q3 | 6 Million AUD | -20.38% |
| 2017 FY | 4.6 Million AUD | 38.31% |
| 2017 Q4 | 6 Million AUD | 0.0% |
| 2017 Q2 | 7.53 Million AUD | 0.0% |
| 2017 Q1 | 7.53 Million AUD | 68.63% |
| 2016 Q2 | 138.85 Thousand AUD | 0.0% |
| 2016 Q1 | 138.85 Thousand AUD | 11.56% |
| 2016 Q4 | 4.46 Million AUD | 0.0% |
| 2016 Q3 | 4.46 Million AUD | 3118.93% |
| 2016 FY | 3.32 Million AUD | 2573.81% |
| 2015 Q1 | - AUD | 0.0% |
| 2015 Q4 | 124.46 Thousand AUD | 0.0% |
| 2015 Q3 | 124.46 Thousand AUD | 0.0% |
| 2015 FY | 124.46 Thousand AUD | 101.4% |
| 2014 FY | 61.8 Thousand AUD | -41.27% |
| 2013 FY | 105.22 Thousand AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 47.928% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -180.183% |
| SQZ Biotechnologies Company | 107.18 Million USD | 81.128% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -91.667% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 84.465% |
| Mesoblast Limited | 667.9 Million USD | 96.971% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -27853.531% |
| Genus plc | 1.02 Billion USD | 98.034% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -1389.199% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -3953.505% |
| Marizyme, Inc. | 22.01 Million USD | 8.115% |
| ContraFect Corporation | 20.67 Million USD | 2.178% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -3126.248% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -5081.951% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -5192.985% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -1312.578% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -387.903% |
| MultiCell Technologies, Inc. | 126.22 USD | -16026340.342% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -2052.688% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 84.259% |
| EV Biologics, Inc. | 431.71 Thousand USD | -4585.642% |
| Q BioMed Inc. | 3.51 Million USD | -475.408% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 42.498% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -2524.892% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -7642.194% |
| Biomind Labs Inc. | 73.81 Thousand USD | -27302.936% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 95.63% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 32.605% |
| Skye Bioscience, Inc. | 11.94 Million USD | -69.413% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -510.58% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -636.566% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -933.025% |
| IMV Inc. | 31.33 Million USD | 35.442% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -2842.398% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -677.067% |
| GB Sciences, Inc. | 103.44 Thousand USD | -19455.474% |
| Alpha Cognition Inc. | 2.45 Million USD | -724.925% |
| HST Global, Inc. | 1526.00 USD | -1325494.561% |
| CSL Limited | 38.02 Billion USD | 99.947% |
| Halberd Corporation | 10.13 Thousand USD | -199570.052% |
| Enzolytics Inc. | 361.7 Million USD | 94.407% |
| Resverlogix Corp. | 8.11 Million USD | -149.274% |
| Affymax, Inc. | 7.44 Million USD | -171.78% |
| SYBLEU INC | 330.46 Thousand USD | -6021.19% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -977.203% |
| argenx SE | 4.54 Billion USD | 99.555% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 27.61% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 57.594% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -88695.808% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -126.039% |
| AVAX Technologies, Inc. | 7.37 Million USD | -174.206% |
| Zenith Capital Corp. | 7410.00 USD | -272890.189% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.403% |
| Ember Therapeutics, Inc. | 184.00 USD | -10993689.674% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -6185.953% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -7639.617% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 95.468% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -1296.188% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | -568.694% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 61.616% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -2079.895% |
| BioStem Technologies, Inc. | 14.56 Million USD | -38.93% |
| ONE Bio Corp. | 70.08 Million USD | 71.137% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -35330.296% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -875595.801% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -1947.495% |
| Agentix Corp. | 261.39 Thousand USD | -7638.788% |
| LadRx Corporation | 2.3 Million USD | -776.499% |
| Cell Source, Inc. | 195.17 Thousand USD | -10264.538% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -4109.401% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -5620.475% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -5620.475% |
| NovAccess Global Inc. | 62.24 Thousand USD | -32396.744% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -3062.414% |
| Itoco Inc. | 1.4 Million USD | -1344.824% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -21046.987% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -18983.559% |
| Kadimastem Ltd | 2.3 Million USD | -777.946% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -26393.141% |
| CytoDyn Inc. | 11.13 Million USD | -81.65% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -14048.626% |
| Mobile Lads Corp. | 52.00 USD | -38901001.923% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -113035.196% |
| Qrons Inc. | 420.00 USD | -4816226.905% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -5147.755% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -3563.8% |
| Rebus Holdings, Inc. | 5000.00 USD | -404471.46% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -4840.764% |
| International Stem Cell Corporation | 5.39 Million USD | -275.298% |
| Bioxytran, Inc. | 137.63 Thousand USD | -14596.939% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -34.841% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -22.013% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -25505.789% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -2239.437% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -169.104% |
| Neutra Corp. | 2851.00 USD | -709425.535% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 37.578% |
| PureTech Health plc | 693.97 Million USD | 97.085% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -150.63% |
| IXICO plc | 15.84 Million USD | -27.674% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -144.247% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 80.422% |
| CSL Limited | 38.02 Billion USD | 99.947% |
| Cellectis S.A. | 333.99 Million USD | 93.943% |